IRIS UniCatt

Iacovelli, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.251
NA - Nord America 1.105
EU - Europa 609
SA - Sud America 307
AF - Africa 37
OC - Oceania 2
Totale 3.311
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.049
SG - Singapore 528
BR - Brasile 265
CN - Cina 240
IT - Italia 157
SE - Svezia 137
VN - Vietnam 136
IN - India 91
FR - Francia 73
DE - Germania 72
BD - Bangladesh 60
JP - Giappone 40
HK - Hong Kong 39
GB - Regno Unito 38
IE - Irlanda 30
ID - Indonesia 26
MX - Messico 24
CA - Canada 21
KR - Corea 16
RU - Federazione Russa 16
PL - Polonia 15
AR - Argentina 14
NL - Olanda 14
IQ - Iraq 12
ZA - Sudafrica 11
ES - Italia 10
FI - Finlandia 10
EC - Ecuador 9
TR - Turchia 9
UA - Ucraina 8
LT - Lituania 7
SA - Arabia Saudita 7
CO - Colombia 6
EG - Egitto 6
IR - Iran 6
AE - Emirati Arabi Uniti 5
PK - Pakistan 5
VE - Venezuela 5
AT - Austria 4
CI - Costa d'Avorio 4
JO - Giordania 4
MA - Marocco 4
UZ - Uzbekistan 4
CL - Cile 3
DZ - Algeria 3
ET - Etiopia 3
HN - Honduras 3
LB - Libano 3
MM - Myanmar 3
MY - Malesia 3
NP - Nepal 3
PH - Filippine 3
AU - Australia 2
CZ - Repubblica Ceca 2
GR - Grecia 2
JM - Giamaica 2
KE - Kenya 2
LU - Lussemburgo 2
MD - Moldavia 2
PE - Perù 2
PY - Paraguay 2
RO - Romania 2
SI - Slovenia 2
TH - Thailandia 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
IS - Islanda 1
KG - Kirghizistan 1
KZ - Kazakistan 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SN - Senegal 1
SR - Suriname 1
Totale 3.311
Salva come PNG Salva come JPEG
Città #
Singapore 285
San Jose 164
Ashburn 138
Chandler 82
Ho Chi Minh City 63
Hyderabad 53
Hefei 50
Beijing 49
Los Angeles 43
Tokyo 40
New York 39
Hong Kong 37
Lauterbourg 32
Frankfurt am Main 31
Rome 31
Dublin 30
Hanoi 29
The Dalles 27
São Paulo 25
Jakarta 20
Milan 20
Seoul 16
Kent 14
Mexico City 13
Chicago 12
Düsseldorf 12
Santa Clara 12
Orem 11
Princeton 11
Warsaw 11
Boston 10
Dallas 10
Houston 10
Boardman 9
Council Bluffs 9
Chennai 8
Curitiba 8
Johannesburg 8
Munich 8
Seattle 8
Atlanta 7
Brooklyn 7
Dearborn 7
Denver 7
Dhaka 7
Palermo 7
Poplar 7
Porto Alegre 7
San Mateo 7
Stockholm 7
Wilmington 7
Buffalo 6
Da Nang 6
Falkenstein 6
Moscow 6
Paris 6
Baghdad 5
Haiphong 5
Helsinki 5
Jeddah 5
Memphis 5
Nanjing 5
Padua 5
Rio de Janeiro 5
Toronto 5
Abidjan 4
Amman 4
Amsterdam 4
Belo Horizonte 4
Bexley 4
Bologna 4
Brasília 4
Cleveland 4
Hebei 4
Lappeenranta 4
London 4
Madrid 4
Messina 4
Montreal 4
Mumbai 4
Phoenix 4
Portsmouth 4
Shanghai 4
Tianjin 4
Addis Ababa 3
Ankara 3
Augusta 3
Brescia 3
Bắc Ninh 3
Cairo 3
City of London 3
Cotia 3
Guaratinguetá 3
Guayaquil 3
Hải Dương 3
Jiaxing 3
Maceió 3
Norwalk 3
Nova Iguaçu 3
Ottawa 3
Totale 1.764
Salva come PNG Salva come JPEG
Nome #
Methylation study of the Paris system for reporting urinary (TPS) categories 136
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine 135
DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group 129
Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers 129
Biomarkers of response to advanced prostate cancer therapy 124
Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives 122
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions 120
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study 115
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations 114
Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma 113
PD-L1 Expression in de Novo Metastatic Castration-sensitive Prostate Cancer 108
The effect of a treatment delay on outcome in metastatic renal cell carcinoma 106
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: A systematic review and meta-analysis 106
Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients 105
Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy 103
Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives 98
Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma 95
Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors 94
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study 92
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma 92
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis 91
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients with Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial 90
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy 90
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study 89
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin 84
Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario 84
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis 83
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis 83
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 82
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 77
Revising PTEN in the era of immunotherapy: New perspectives for an old story 76
Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis 75
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 57
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study 51
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial 14
Patient-derived organoids in renal cell carcinoma: A review of methodologies and applications 9
A novel comprehensive cancer genome profiling for non-metastatic prostate cancer: study protocol with FPG500 to detect actionable alterations representative of progressive disease 5
Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future Directions 5
BRCA2 and genetic mutations in prostate cancer: an updated practical guide on “when and how” testing across international guidelines 2
Totale 3.383
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.563
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.563
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202286 6 0 3 13 10 0 2 11 3 4 23 11
2022/2023258 54 42 13 25 30 14 17 19 26 2 10 6
2023/2024177 11 36 9 22 5 22 13 1 7 12 17 22
2024/2025702 6 4 33 10 18 18 69 30 77 124 154 159
2025/20262.092 282 90 131 310 359 80 264 114 109 134 127 92
Totale 3.383